What is PathologyWatch?
PathologyWatch operates as a specialized provider of digital dermatopathology solutions, effectively bridging the gap between clinical diagnostics and operational efficiency. The company offers a comprehensive suite of services, including streamlined test result management, digital connectivity tools, and clinician education resources. By focusing on the specific needs of dermatology practices, PathologyWatch optimizes patient outcomes and reduces administrative friction. Its market position is defined by its ability to digitize traditionally manual processes, thereby enabling practitioners to focus on high-value patient care while maintaining rigorous diagnostic standards.
How much funding has PathologyWatch raised?
PathologyWatch has raised a total of $34.3M across 4 funding rounds:
Unspecified
$2.3M
Series A
$5M
Unspecified
$2M
Series B
$25M
Unspecified (2019): $2.3M, investors not publicly disclosed
Series A (2020): $5M led by SpringTide Investments and Rock Creek Capital
Unspecified (2020): $2M supported by BioVentures Inc, Sky Ventures Group, Neue Fund, BeniVC, and Lateral Capital
Series B (2021): $25M featuring Ceros Capital Markets, Rock Creek Capital, SpringTide, and Spark Growth Ventures
Key Investors in PathologyWatch
Ceros Capital Markets
A global investing platform specializing in fundraising for MedTech and Biotech companies, with a focus on disruptive technologies in medical devices and digital health.
Spark Growth Ventures
A community-driven venture capital firm based in San Diego, dedicated to supporting mid-stage technology startups through a vast network of industry experts and founders.
Lateral Capital
A mission-driven venture fund that partners with visionary entrepreneurs to build essential digital infrastructure, offering flexible and patient capital from Seed to Growth stages.
What's next for PathologyWatch?
With the successful completion of its latest financing round, PathologyWatch is poised to scale its digital infrastructure and expand its footprint in the competitive MedTech landscape. The strategic allocation of this capital will likely focus on enhancing its proprietary diagnostic platform, broadening its reach to new clinical networks, and deepening its integration capabilities. As the company transitions into its next phase of growth, it remains committed to fostering innovation in non-invasive diagnostic procedures, ensuring that dermatology practices are equipped with the necessary tools to navigate the complexities of modern healthcare delivery.
See full PathologyWatch company page
